About Jamie Young, DVM, PhD, Diplomate ACVP

Jamie Young, DVM, PhD, Diplomate ACVP has over 15 years of pharmaceutical industry experience as a toxicologic pathologist including 10 years as a Pathologist with Eli Lilly and Company. She one of a small number of veterinary pathologists who is double boarded in both clinical and anatomic pathology. Dr. Young has provided pathology support for a wide range of study types ranging from In Vivo Pharmacology, Discovery Toxicology, NonClinical Toxicology and Safety Assessment, and Carcinogenicity studies, and been a member of a number of drug development teams. She has expertise in oncology drug development and neuropathology. Dr. Young chaired the STP/ASVCP Clinical Pathology in Carcinogenicity Studies Working Group and was a member of the Carcinogenicity Working Group of the Predictive Safety Testing Consortium.

The Integrated Role of the Project Pathologist

The Integrated Role of the Project Pathologist

When you think of a pathologist, you may picture a scientist peering through a microscope, viewing slides and making notes about a disease state, then moving on to the next sample. Indeed, the classic role of many contract pathologists is to evaluate large numbers of tissue slides and author pathology reports. However at Covance, the Lead Optimization Pathology group plays a much greater role in drug development.

The Lead Optimization Pathology group offers Project Pathologists—a staff pathologist with therapeutic area expertise who is assigned to a project and intimately involved in supporting the early drug development in both efficacy and non-GLP toxicity studies. As ACVP board certified veterinary pathologists with Ph.D. degrees and past experience working in large pharmaceutical companies, the staff can offer in-depth pathology support for both small and big clients. Continue reading